Scope of application

Polyoxidonium^® is administered in children (lyophilisate — from 6 months, tablets — from 3 years, suppositories — from 6 years) for the treatment and prevention of influenza, ARVI, as well as other acute and chronic infections of the ENT organs, upper and lower respiratory tract of the viral and bacterial etiology.¹

Polyoxidonium^® activates immunity to combat the virus via the synthesis of interferons, helps to alleviate inflammation and intoxication, has a prolonged effect increasing the body's resistance to repeated infections, and helps to reduce the number of bacterial complications.^2,3,4,5 In case of topical administration, contributes to the increase in the antimicrobial activity of macrophages and neutrophils, and the increase in the concentration of lysozyme in the nasal secretion.³ Does not contain components of plant and animal origin, can be administered in children having an allergy.⁴ No cumulative effect.¹

1. Patient information leaflet for Polyoxidonium^®.
2. Glushkova, E.F., Surovenko, T.N. (2019). Issues of treatment of upper respiratory tract infections: new approaches. Pediatrics (Appendix to Consilium Medicum), 1, 52–56.
3. Morozova, S.V. (2010). The use of Polyoxidonium^® immunocorrecting drug in acute infectious inflammatory pathology of ENT-organs. Russian Medical Journal, 24, 14–53.
4. Uchaikin, V.F. (2017). On the issue of expanding the indications of the use of an immunomodulating drug in the treatment and prevention of influenza and acute respiratory infections in young children. Children Infections, 16(3), 54–58.
5. Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.

The use of Polyoxidonium^® for the treatment of acute and chronic infectious and inflammatory diseases of the upper respiratory tract helps to normalize nasal breathing by the 4^th day, reduce the duration of catarrhal phenomena 2 times, normalize the composition of the nasopharynx microflora and reduce the size of hypertrophied pharyngeal tonsils.¹

Besides, Polyoxidonium^® contributes to the decrease in the number of complications and reoccurrence of infectious diseases of the respiratory tract.^1,2

Polyoxidonium^® is included in the national guidelines for Otorhinolaryngology (GEOTAR-Media, 2014)³, Standards of Medical Care Otorhinolaryngology (GEOTAR-Media, 2016), in the guidelines from the National Medical Association of Otorhinolaryngologists "Acute Sinusitis" and "Allergic Rhinitis, Etiology, Pathogenesis and Features of Pharmacotherapy".

1. Morozova, S.V. (2010). The use of Polyoxidonium^® immunocorrecting drug in acute infectious inflammatory pathology of ENT-organs. Russian Medical Journal, 24, 14–53.
2. Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.
3. Uchaikin, V.F. (2017). On the issue of expanding the indications of the use of an immunomodulating drug in the treatment and prevention of influenza and acute respiratory infections in young children. Children Infections, 16(3), 54–58.

ARVIs may cause exacerbation of bronchial asthma. Due to the absence of components of animal and plant origin, Polyoxidonium^® can be used as part of combination treatment of infectious diseases associated with bronchial asthma.

Polyoxidonium^® is also used for influenza and ARVI prevention. A decrease in the susceptibility to acute respiratory infections contributes to a decrease in the number of exacerbations and an increase in the duration of remission.^1,2 The use of Polyoxidonium^® as part of combination treatment of community-acquired pneumonia helps shorten the duration of the intoxication period and alleviate the course of the disease. In addition, when Polyoxidonium^® is included in combination treatment, a faster elimination of clinical symptoms of the disease is observed together with a positive X-ray dynamics in 92% of patients.³

1. Patient information leaflet for Polyoxidonium^®.
2. Gornostayeva, Yu.A. (2015). Approaches to the treatment of upper respiratory tract infections in patients with allergic pathology. Medical Council, 7.
3. Mavzyutova, G.A., Mukhamadiyeva, L.R., Fazlyeva, R.M., Mirsayeva, G.Kh., Tyurina, E.B. (2015). Rational immunotherapy in the combination treatment of community-acquired pneumonia. Medical Council, 16. URL: https://cyberleninka.ru/article/n/ratsionalnaya-immunokorrektsiya-v-kompleksnoy-terapii-vnebolnichnoy-pnevmonii (last accessed date: 01.07.2019).

Polyoxidonium^® is used to increase the effectiveness of combination treatment of infectious and inflammatory diseases of the female genital organs (vaginitis, cervicitis, candidiasis, PID, etc.).¹

Polyoxidonium^® inclusion in the initial treatment helps reduce the period of clinical manifestations of inflammation, eliminate residual itching, burning, irritation of the mucosae during and after causal treatment, improve well-being as early as on the 2^nd day after the beginning of the treatment.^2,3

1. Patient information leaflet for Polyoxidonium^®.
2. Shulzhenko, A.E., Schubelko, R.V., Zuikova, I.N. (2016). Recurrent mixed infections of the urogenital tract in women: a strategy for the correction of mucosal immunity. Consilium Medicum, vol. 18, No. 6.
3. Lebedev, V.A., Pashkov, V.M. (2011). Modern principles of colpitis therapy. Difficult Patient, vol. 9, No. 8–9.

Polyoxidonium^® is used to increase the effectiveness of combination treatment of infectious and inflammatory diseases of the genitourinary system (cystitis, urethritis, pyelonephritis, prostatitis).¹

Polyoxidonium^® included in the initial treatment promotes the elimination of bacterial and fungal pathogens in 98% of patients, provides for 2 times faster relief of leukocyturia and dysuria symptoms and an increase in the recurrence period — more than 6 months.^2,3

1. Patient information leaflet for Polyoxidonium^®.
2. Derevyanko, T.I., Ryzhkova, E.V., Tolchanov, S.A. (2012). Application of Polyoxidonium^® in the treatment of women with chronic infectious diseases of the lower urinary tract. Effective Pharmacotherapy, 2.
3. Solovyev, A.M. (2017). Immunotherapy in combination treatment of bacterial genitourinary tract infections. Consilium Medicum, 19(6), 68–78.

Polyoxidonium^® acts on phagocytic cells and natural killer cells, stimulates antibody production and the synthesis of alpha and gamma interferons.¹

Infectious and inflammatory process development is almost always accompanied by the formation of neutrophil extracellular traps, which, in addition to a positive protective role, also have a negative cytotoxic effect. An in vitro experiment shows that Polyoxidonium^® decreases the formation of neutrophil extracellular traps.² However, the bactericidal properties of neutrophils are not suppressed, but operate through better mechanisms. Polyoxidonium^® enhances the bactericidal properties of leukocytes and their phagocytic activity.³

1. Patient information leaflet for Polyoxidonium^®.
2. Pinegin, B.V., Dagil, Yu.A., Vorobyeva, N.V., Paschenkov, M.V. (2019). Azoximer bromide effect on the neutrophil extracellular traps formation. Russian Medical Journal.
3. . Dyakonova, V.A., Burakov, V.V., Sharonov, G.V., Pinegin, B.V. Study of interaction between the Polyoxidonium immunomodulator and the human immune system cells. National Research Center Institute of Immunology of FMBA of Russia, Moscow, Lomonosov Moscow State University, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry.

Polyoxidonium^® is used as part of combination treatment of oncological diseases during chemo- and radiation therapy in order to reduce the nephro- and hepatotoxic effects of drugs.¹ Administration of Polyoxidonium^® in breast cancer patients between the FAC courses improved treatment tolerability and reduced the incidence of side effects.²

1. Patient information leaflet for Polyoxidonium^®.
2. Artamonova, E.V., Korotkova, O.V., Zabotina, T.N., Fedenko, A.A., Kadagidze, Z.G., Manzyuk, L.V. (2005). Results of Polyoxidonium administration in patients with breast cancer. Russian Biotherapeutic Journal, 1.

Polyoxidonium^® is used for the reconvalescence and prevention of subsequent relapses of infectious and inflammatory diseases of various localization.¹

A double-blind placebo-controlled study showed that Polyoxidonium^® was effective for the prevention of ARI in frequently ill children: in 6 months after the end of therapy in children receiving Polyoxidonium^®, a decrease in the frequency of ARIs (2 times, compared with those who did not receive Polyoxidonium^® as part of ARI combination treatment) was observed.²

1. Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.
2. Uchaikin, V.F. (2017). On the issue of expanding the indications of the use of an immunomodulating drug in the treatment and prevention of influenza and acute respiratory infections in young children. Children Infections, 16(3), 54–58.